Acute myelomonocytic leukemia
Drug research and approvals for acute myelomonocytic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 49 studies of acute myelomonocytic leukemia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 49
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic…NCT07582172 · Phase 2 · City of Hope Medical Center · starts Nov 5, 2026
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCTNCT07302776 · Phase 1 · Stanford University · starts Jul 21, 2026
- Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor…NCT07046078 · Phase 2 · Fred Hutchinson Cancer Center · starts Sep 26, 2025
- A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasNCT06994676 · Phase 1 · Crossbow Therapeutics, Inc. · starts Jul 16, 2025
- A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)NCT06950034 · Phase 1 · Solu Therapeutics, Inc · starts Mar 13, 2025
- Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell…NCT06928662 · Phase 1 / Phase 2 · Fred Hutchinson Cancer Center · starts Sep 23, 2025
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients…NCT06904066 · Phase 1 · National Cancer Institute (NCI) · starts Oct 28, 2026
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in…NCT06859424 · Phase 2 · Center for International Blood and Marrow Transplant Research · starts Jul 25, 2025
Approved 1
- DoxorubicinDNA topoisomerase II alpha inhibitor
Phase 3 12 of 13
- CytarabineDNA inhibitor
- DaunorubicinDNA topoisomerase II alpha inhibitor
- BusulfanDNA inhibitor
- AldesleukinInterleukin-2 receptor agonist
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- ThioguanineInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- AsparaginaseAsparagine hydrolytic enzyme
- ValspodarP-glycoprotein 1 inhibitor
- IdarubicinDNA topoisomerase II alpha inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- CyclophosphamideDNA inhibitor
Phase 1 or earlier 2
- UCN-01Cyclin-dependent kinase 2 inhibitor
- Perifosine
How its trials ended
168 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 57 whose ending is known, 33% met their primary endpoint, 11% missed it and 56% stopped early.
- Completed, result not reported7343%
- Ongoing3320%
- Met its primary endpoint1911%
- Stopped: other or unclear1610%
- Stopped: enrollment or feasibility74%
- Missed its primary endpoint64%
- Stopped: sponsor or business decision53%
- Status unknown53%
- Stopped: lack of efficacy21%
- Stopped: funding21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA